“And we remain on track to deliver high single-digit organic sales growth and double-digit EPS growth.”

In context

“le sensor used for the early detection of heart failure. And vascular growth of 5% was led by continued strong performance in our market-leading portfolio of vessel closure products and increasing contributions from ESPRIT, our below-the-knee resorbable stent. In August, we received CE mark for ESPRIT, and we look forward to bringing this innovative technology to people outside the United States who suffer from peripheral artery disease. Lastly, neuromodulation growth of 7% was led by strong performance of our Eterna rechargeable spinal cord stimulation device in international markets, reflecting both continued uptake in existing markets and launches in new markets. So in summary, we delivered another very good quarter. Our pipeline has been highly productive and continues to fuel growth. And we remain on track to deliver high single-digit organic sales growth and double-digit EPS growth. I'll now turn over the call to Philip. Thanks, Robert. Philip Boudreau: As Mike mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on an organic basis. Turning to our third quarter results, sales increased 5.5% or 7.5% when excluding COVID testing-related sales. Adjusted earnings per share of $1.30 was in line with consensus estimate. Philip Boudreau: Foreign exchange had a favorable year-over-year impact of 1.4% on third-quarter sales, which was less favorable than what we forecasted at the time of our earnings call in July. Regarding other aspects of the P&L, the adjusted gross margin profile was 55.8% of sales, which as expected reflects a decrease compared to the prior year due to the impact of tariffs. Adjusted R&D was 6.4% of sales,”